Literature DB >> 30320374

In vitro analysis of microRNA-26a in chronic lymphocytic leukemia cells.

Jing Li1, Chang-Kui Sun1.   

Abstract

microRNA (miRNA)‑26a‑loaded liposomes were prepared in the present study for effective treatment of leukemia. The results demonstrated that miRNA‑26a reduced the viability of chronic lymphocytic leukemia (CLL) cells in a concentration‑dependent manner. Cells treated with miRNA‑26a‑loaded liposomes exhibited increased rates of apoptosis, as determined by flow cytometry and Hoechst 33342 staining. Western blot analysis revealed an increased apoptotic effect of miRNA‑26a‑loaded liposomes compared with control. Treatment with these liposomes resulted in significant downregulation of the expression of the miRNA‑26a target genes, myeloid cell leukemia 1 and cyclin‑dependent kinase 6. Taken together, the results of the present study indicate that miRNA‑26a exerts apoptosis‑inducing and anticancer effects on leukemia cells, suggesting therapeutic potential. This approach may be possible to extrapolate to other neoplasms, including lymphomas and acute myeloid leukemia.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30320374      PMCID: PMC6202071          DOI: 10.3892/ijmm.2018.3925

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  26 in total

Review 1.  Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571.

Authors:  Ramadevi Nimmanapalli; Kapil Bhalla
Journal:  Oncogene       Date:  2002-12-09       Impact factor: 9.867

2.  Requirement of activation of JNK and p38 for environmental stress-induced erythroid differentiation and apoptosis and of inhibition of ERK for apoptosis.

Authors:  Y Nagata; K Todokoro
Journal:  Blood       Date:  1999-08-01       Impact factor: 22.113

3.  BCR/ABL promotes dendritic cell-mediated natural killer cell activation.

Authors:  Magali Terme; Christophe Borg; François Guilhot; Carole Masurier; Caroline Flament; Erwin F Wagner; Sophie Caillat-Zucman; Alain Bernheim; Ali G Turhan; Anne Caignard; Laurence Zitvogel
Journal:  Cancer Res       Date:  2005-07-15       Impact factor: 12.701

Review 4.  Applications of nanoparticles in treatment and diagnosis of leukemia.

Authors:  Govind Soni; Khushwant S Yadav
Journal:  Mater Sci Eng C Mater Biol Appl       Date:  2014-11-11       Impact factor: 7.328

Review 5.  A review of supportive care and recommended preventive approaches for patients with chronic lymphocytic leukemia.

Authors:  Jasleen K Randhawa; Alessandra Ferrajoli
Journal:  Expert Rev Hematol       Date:  2016-02-24       Impact factor: 2.929

6.  Layer-by-layer assembly of liposomal nanoparticles with PEGylated polyelectrolytes enhances systemic delivery of multiple anticancer drugs.

Authors:  Thiruganesh Ramasamy; Ziyad S Haidar; Tuan Hiep Tran; Ju Yeon Choi; Jee-Heon Jeong; Beom Soo Shin; Han-Gon Choi; Chul Soon Yong; Jong Oh Kim
Journal:  Acta Biomater       Date:  2014-08-25       Impact factor: 8.947

7.  The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia.

Authors:  Ulf Klein; Marie Lia; Marta Crespo; Rachael Siegel; Qiong Shen; Tongwei Mo; Alberto Ambesi-Impiombato; Andrea Califano; Anna Migliazza; Govind Bhagat; Riccardo Dalla-Favera
Journal:  Cancer Cell       Date:  2010-01-07       Impact factor: 31.743

8.  MicroRNAs in human cancer: from research to therapy.

Authors:  Massimo Negrini; Manuela Ferracin; Silvia Sabbioni; Carlo M Croce
Journal:  J Cell Sci       Date:  2007-06-01       Impact factor: 5.285

9.  Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

Authors:  Andrew W Roberts; Matthew S Davids; John M Pagel; Brad S Kahl; Soham D Puvvada; John F Gerecitano; Thomas J Kipps; Mary Ann Anderson; Jennifer R Brown; Lori Gressick; Shekman Wong; Martin Dunbar; Ming Zhu; Monali B Desai; Elisa Cerri; Sari Heitner Enschede; Rod A Humerickhouse; William G Wierda; John F Seymour
Journal:  N Engl J Med       Date:  2015-12-06       Impact factor: 91.245

Review 10.  siRNA Versus miRNA as Therapeutics for Gene Silencing.

Authors:  Jenny K W Lam; Michael Y T Chow; Yu Zhang; Susan W S Leung
Journal:  Mol Ther Nucleic Acids       Date:  2015-09-15       Impact factor: 10.183

View more
  1 in total

Review 1.  Targeted Drug Delivery for Chronic Lymphocytic Leukemia.

Authors:  Makhloufi Zoulikha; Wei He
Journal:  Pharm Res       Date:  2022-03-07       Impact factor: 4.200

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.